Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AT-752

Small molecule · developed by Atea Pharmaceuticals

Phase 2 Most advanced trial (none active)
AVIR Developer
1 Registered trials

What is AT-752?

AT-752 is a drug name with no mechanism or target described in the available source texts. It is studied in dengue fever.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Infectious disease
Developer
Atea Pharmaceuticals, Inc. (AVIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05466240 Phase 2 Dengue Fever Terminated AVIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dengue Fever

More from Atea Pharmaceuticals

AT-527 Phase 1 AT-587 Phase 1 AT-777 Phase 1/2 Bemnifosbuvir Phase 3 Bemnifosbuvir-Ruzasvir Phase 3 Ethinyl Estradioll/Levonorgestrel Phase 1 Ruzasvir Phase 2 Treatment A-Bemnifosbuvir/Ruzasvir FDC Phase 1

Follow AVIR, the company behind AT-752

See AVIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.